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Abstract
Background: In humans, inflammation of either the urinary bladder or the distal colon often results in sensory
cross-sensitization between these organs. Limited information is known about the mechanisms underlying this
clinical syndrome. Studies with animal models have demonstrated that activation of primary afferent pathways may
have a role in mediating viscero-visceral cross-organ sensitization.
Methods: Colonic inflammation was induced by a single dose of tri-nitrobenzene sulfonic acid (TNBS) instilled
intracolonically. The histology of the colon and the urinary bladder was examined by hematoxylin and eosin (H&E)
stain. The protein expression of transient receptor potential (TRP) ion channel of the vanilloid type 1 (TRPV1) and
brain-derived neurotrophic factor (BDNF) were examined by immunohistochemistry and/or western blot. The inter-
micturition intervals and the quantity of urine voided were obtained from analysis of cystometrograms.
Results: At 3 days post TNBS treatment, the protein level of TRPV1 was increased by 2-fold (p < 0.05) in the
inflamed distal colon when examined with western blot. TRPV1 was mainly expressed in the axonal terminals in
submucosal area of the distal colon, and was co-localized with the neural marker PGP9.5. In sensory neurons in the
dorsal root ganglia (DRG), BDNF expression was augmented by colonic inflammation examined in the L1 DRG, and
was expressed in TRPV1 positive neurons. The elevated level of BDNF in L1 DRG by colonic inflammation was
blunted by prolonged pre-treatment of the animals with the neurotoxin resiniferatoxin (RTX). Colonic inflammation
did not alter either the morphology of the urinary bladder or the expression level of TRPV1 in this viscus. However,
colonic inflammation decreased the inter-micturition intervals and decreased the quantities of urine voided. The
increased bladder activity by colonic inflammation was attenuated by prolonged intraluminal treatment with RTX
or treatment with intrathecal BDNF neutralizing antibody.
Conclusion: Acute colonic inflammation increases bladder activity without affecting bladder morphology. Primary
afferent-mediated BDNF up-regulation in the sensory neurons regulates, at least in part, the bladder activity during
colonic inflammation.
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Clinical evidence has shown sensory cross-sensitization
between the urinary bladder and the distal colon [1-5].
Patients with inflammatory bowel disease (IBD) are
more likely to experience nocturia and some forms of
urinary urge incontinence compared to the non-IBD
population [3]. Other forms of cross-organ sensitization
are also observed in experimental animals. Rats or mice
induced for cystitis or colitis exhibit decreases in the
threshold to stimulation of the hindpaw demonstrating
a viscero-somatic cross-sensitization [6-8]. Inflammation
in the lower extremities also causes an enhanced
response to colorectal distension [6,9,10], suggesting
that visceral sensitivity can also be influenced by the
irritation of non-visceral organs. Recent studies in
anesthetized animals have shown that colonic irritation
leads to neurogenic cystitis as manifested by irritative
micturition patterns and increases in micturition fre-
quency [11,12]. Conversely cystitis induced by cyclopho-
sphamide also increases colorectal afferent sensitivity in
mice [13]. These observations indicate a broad phenom-
enon between organ to organ sensory cross-interaction.
The currently proposed mechanism and pathways
underlying cross-organ sensitization may involve activa-
tion of primary afferent pathways [14-16]. Rodents with
experimentally induced colonic inflammation exhibit an
enhanced firing of bladder C-fibers in response to blad-
der distension [12,17]. Activation of primary afferent
pathways by one form of peripheral organ irritation may
lead to cross-activation of the primary afferent neurons
projecting to another peripheral organ [18,19] or lead to
central sensitization in the spinal cord [20]. This is par-
ticularly true with colonic inflammation which not only
sensitizes colonic afferentn e u r o n sb u ta l s oa l t e r st h e
molecular profiles of bladder afferent neurons in the
dorsal root ganglia (DRG). It has been reported that
colonic inflammation significantly increases the expres-
sion level of calcitonin gene-related peptide (CGRP)
[19], and increases the currents of TTX-resistant (TTX-
R) Na
+ channels [18] in specifically labeled bladder sen-
sory neurons.
The transient receptor potential (TRP) ion channel of
the vanilloid type 1 (TRPV1) is involved in many sys-
tems during inflammation and sensory sensitization
[21-26]. TRPV1 receptor antagonist has prevented the
visceral hypersensitivity to intracolonic mechanical and
chemical stimulation [24]. Animals deficient in TRPV1
exhibit reduced responses of primary sensory afferent
fibers to mechanical distension of the colon [22]. The
activity of TRPV1 is regulated by potent agonist such as
resiniferatoxin (RTX) in a biphasic fashion. Acute RTX
treatment results in enhanced TRPV1 activity, while a
prolonged treatment with RTX produces desensitization
of the receptor [27-31]. In animal studies, a prolonged
RTX treatment is demonstrated for its effects on desen-
sitization of unmyelinated nociceptive C-fiber afferents
[27,29,30]; in humans, RTX has also been suggested for
therapeutic intervention of visceral disorders [28,32,33].
In our previous studies, we have successfully used RTX
to block colonic inflammation-induced TrkA up-regula-
tion in the colonic afferent neurons [34]. These studies
suggest a role of TRPV1 in inflammation-induced sen-
sory plasticity.
The brain-derived neurotrophic factor (BDNF) has
been postulated to play an important role in inflamma-
t i o n - i n d u c e ds e n s o r yh y p e r s e n s i t i v i t yb ym o d u l a t i n g
the sensitivity of primary afferents [19,35-37]. Blockade
of BDNF action with spinal intrathecal injection of
BDNF/TrkB antiserum has significantly reduced
inflammation-induced hyperalgesia [38,39]. Systemic
knockdown of BDNF activity by intraperitoneal injec-
tion of BDNF neutralizing antibody also reverses coli-
tis-induced colonic hypersensitivity [40]. Conversely,
intraperitoneal injection of BDNF protein significantly
enhances colonic sensitivity and decreases the colonic
reaction threshold in healthy rats [40]. A recent study
has shown that with colitis BDNF(+/-) mice exhibit
weaker visceral responses to colorectal distension and
lower sensitivity in the colon than BDNF(+/+) mice
[41]. These findings imply that the increased level of
BDNF in primary sensory neurons in the DRG during
colonic inflammation [37] may have a role in mediat-
ing visceral hypersensitivity.
Materials and methods
Intracolonic instillation of TNBS to induce localized
colonic inflammation
Adult male Sprague-Dawley rats (150-200 g) from Har-
lan Sprague Dawley, Inc. were used for this study. To
induce inflammation in the distal colon, fasted rats were
anesthetized (2% isoflurane, SurgiVet, Smiths Medical
P M ,I n c .W a u k e s h a ,W I ) .As i n g l ed o s eo fT N B Sw a s
instilled into the lumen of the colon 6 cm proximal to
the anus at a dose of 90 mg/kg (1.5 mL/kg of 60 mg/
mL solution in 50% EtOH) through a polyethylene (PE)
catheter. Control animals received a similar volume of
50% EtOH. Examinations were performed 3 days post
TNBS or vehicle treatment.
Harvest of tissues
The distal colon and the urinary bladder from control
and the inflamed animals were removed, fixed with 4%
paraformaldehyde and sectioned transversely at a thick-
ness of 10 μm, or the distal colon underwent whole
mount dissection for separation of the mucosal, submu-
cosal, and muscle layers. The DRGs were sectioned at a
thickness of 20 μm. Tissues from control and experi-
mental animals were handled in an identical manner.
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morphology and inflammation of the colon and the
urinary bladder
Transverse sections of the distal colons and urinary
bladders from all animals were stained with an H & E
staining kit according to the protocol provided by the
manufacture (Richard-Allan-Scientific, Kalamazoo, MI).
The sections were examined with a Zeiss brightfield
microscope. The histology score was graded to reflect
the severity of the visceral inflammation (1, no inflam-
mation; 2, very low inflammation; 3, low level of infiltra-
tion; 4, high level of infiltration and vascular density; 5,
transmural infiltrations and high vascular density). The
increases in the thickness of the muscular wall, the
width of the submucosal space (lamina propria), and the
depth of the mucosal layer were also considered as signs
of inflammation.
Immunohistochemistry
Sections and the tissue layers were incubated with
blocking solution containing 3% normal donkey serum
in PBST (0.3% Triton X-100 in 0.1 M PBS, pH 7.4) for
30 min followed by rabbit anti-TRPV1 (1:1000, Chemi-
con International Inc., CA), rabbit anti-BDNF (1:500,
Santa Cruz, CA), and/or sheep anti-BDNF (1:200, Che-
micon International Inc., CA) primary antibodies over-
night at 4°C. After rinsing (3 × 10 min with 0.1 M PBS),
tissues were incubated with Alexa 594-conjugated spe-
cies-specific secondary antibody for 2 hours at room
temperature. Some of the tissues were also co-stained
with guinea pig anti-PGP9.5 primary antibody (1:1000,
Chemicon International Inc., CA) followed by Alexa
488-conjugated species-specific secondary antibody. Fol-
lowing washing, the slides were coverslipped with Citi-
fluor (Citifluor Ltd., London). Immunostaining in the
absence of primary or secondary antibody was assessed
for background evaluation. The specificity of the antibo-
dies was also evaluated with western blot or pre-absorp-
tion assay.
Tissue sections were viewed and analyzed under a
Zeiss fluorescent photomicroscope. DRG neurons
expressing BDNF were counted in 4 to 6 sections of
each DRG, and expressed as mean ± SE for n animals.
Similar sized sections were chosen using the microscope
measurement program and all the positive cells were
counted in the sections. The results were expressed as
number of cells per section. To avoid double counting,
we have chosen every third DRG section for BDNF
immunostaining. For analysis of the TRPV1 immunor-
eactivity in the distal colon, three random microscopy
fields were chosen from each section with caution to
avoid field overlap. Each field was positioned to view a
similar morphological area covering the entire width of
the colon that showed positive TRPV1 stain. The
number of the positive stain in each field was counted
and averaged within each animal. The size of the field
was measured. The results were expressed as number of
TRPV1 stain per mm
2.
Protein extraction and western blot
Segments from the distal colon were homogenized in
solubilization buffer containing 50 mM Tris-HCl, 150
mM NaCl, 1 mM EDTA, 1% Triton X-100, and 100
mM NaF supplemented with protease and phosphatase
inhibitor cocktails (Sigma, St. Louis, MO). The homoge-
nate was centrifuged at 20,200 g for 10 min at 4°C, and
the supernatant was removed to a fresh tube for further
analysis. The protein concentration was determined
using Bio-Rad DC protein assay kit.
Proteins were separated on a 10% SDS-PAGE gel and
transferred to a nitrocellulose membrane. The mem-
brane was blocked with 5% milk in Tris-buffered saline
for 1 hour and then incubated with rabbit ant-TRPV1
(1:1000) antibody followed by goat anti-rabbit IRDye
800 CW. For internal loading control, the same mem-
brane was stripped and re-probed with antibody against
b-actin (1:2000, Sigma). The bands were identified and
analyzed with the ODYSSEY infrared imaging system
(Li-cor Biosciences, Lincoln, NE). The expression level
of the target protein in control animal from each inde-
pendent experiment was considered as 1, and the rela-
tive expression level of the target protein in
experimental animals was adjusted as a ratio to its inter-
nal loading control in each independent experiment.
Drug delivery to animals
To specifically desensitize or destroy the colonic affer-
ents, RTX was dissolved in 10% Tween-80, 10% ethanol,
and normal saline and administered intracolonically
(into the lumen of the colon) at a dose of 250 μg/kg/2
mL 10 days prior to test. BDNF antibody or control IgG
(100 μg/kg body weight, Santa Cruz, CA) was delivered
into the subarachnoid space of the spinal cord via an
intrathecal (i.t.) catheter (No. 0007740, Alzet) connected
to an osmotic-pump (Alzet 2001) four days before
TNBS instillation, and was continuously delivered until
the day of examination which was 3 days post TNBS
treatment. The tip of the catheter was positioned at the
L4-L5 spinal level and was confirmed after euthanasia of
the animals. This delivery site was chosen because of its
position located in the middle of L1 and S1 segments
w h e r ew ef o u n dt h a tB D N Fw a su p - r e g u l a t e dd u r i n g
colitis. This procedure was done under anesthesia (2.5%
isoflurane).
Measurement of urinary bladder micturition pattern
Under anesthesia (2.5% isoflurane), a lower midline
abdominal incision was performed and a PE-50 catheter
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incision made by an 18 G needle at the tip of the blad-
der dome. The catheter was secured in place with a 6-0
nylon purse-string suture. The distal end of the tubing
was externalized at the back of the neck and the rat was
allowed to recover. Four days after the catheter was
implanted, the animal was placed into a recording
chamber (Med Associates, St. Albans, VT). The distal
end of the catheter was connected via a T tube to a
pressure transducer and a syringe pump (Med Associ-
ates, St. Albans, VT). Animals were allowed to recover
from anesthesia and explore the new environment. The
baseline of the bladder pressure was obtained before a
0.9% saline solution was infused into the bladder at a
rate of 9 mL/h according to the manufacture’ss u g g e s -
tions. After initial stabilization, the micturition pattern
of the urinary bladder was recorded for a period of 20
to 30 min. No particular time of the day was chosen for
each animal. Control animals and animals receiving
treatment were randomly assigned for testing during the
day. The bladder inter-micturition intervals (seconds
between two voiding) were measured, analyzed and
expressed as seconds/interval. The quantity of urine of
each voiding was automatically weighed by a scale inte-
grated in the system, and was analyzed and expressed as
gram (g).
Statistical analysis
The results from each study were presented as mean ±
SE for n animals. Comparison between control and
experimental groups was made by using a one-way
ANOVA. When two groups were compared, a student’s
t test was used. Differences between means at a level of
p ≤ 0.05 were considered to be significant.
Results
Colonic inflammation increased TRPV1 expression in the
distal colon but not in the urinary bladder
We compared the histology of the distal colon and the
urinary bladder before and after induction of colonic
inflammation. H&E staining (Figure 1A-D) showed that
the distal colon had the appearance of severe inflamma-
tory infiltration, edema, loss of the mucosal architecture,
high level of vascular density, and increases in the thick-
ness of muscular wall and the width of the submucosal
spaces (compare Figure 1B to 1A). The histology of the
urinary bladder appeared normal in terms of the struc-
ture and folds of the urothelium, the size of the gap of
the suburothelium space, and the thickness of the mus-
cular wall (compare Figure 1D to 1C; Figure 1I shows
the relative damage scores of the colon and the urinary
bladder). To characterize the sensory profile in the distal
colon and the urinary bladder, we examined the expres-
sion of the sensory marker TRPV1 in these organs with
immunohistochemistry and western blot techniques.
During colonic inflammation, the TRPV1-like immunor-
eactivity was dramatically enhanced within the muscular
layer (indicated by *) and the submucosal plexus (indi-
cated by #) of the distal colon (Figure 1F) when com-
pared to the non-inflamed distal colon (Figure 1E, J).
The density of TRPV1 immunoreactivity was not altered
in the urinary bladder before (Figure 1G) and after (Fig-
ure 1H) induction of colonic inflammation. To examine
the specificity of the TRPV1-immunoreactive structures
in the distal colon, we performed pre-absorption assay
with a TRPV1 blocking peptide (5 μg/mL, Santa Cruz,
CA) and found that this blocking peptide completely
abolished the TRPV1-like immunoreactivity in both
regions of the muscular layer and the submucosal area
(compare Figure 2B to 2A), suggesting that the punctu-
ated staining in the distal colon by this TRPV1 antibody
was specific TRPV1 immunoreactivity. Further examina-
tion with double immunostaining showed that the
TRPV1 immunoreactivity in the inflamed distal colon
was expressed in PGP9.5 positive structures (Figure 2C-
H). These co-localization studies were conducted with
transverse sections (Figure 2C-E) and the whole-mount
preparation of the inflamed distal colon (Figure 2F-H).
Both methods demonstrated consistent results showing
that all TRPV1 immunoreactivity was expressed in
PGP9.5 positive structures (Figure 2C-H, white arrows),
but not all PGP9.5 positive structures contained TRPV1
(Figure 2C-H, blue arrows).
Western blot results confirmed the findings above
showing that the protein expression level of TRPV1 was
increased by 2-fold (p < 0.05) at day 3 post induction of
colonic inflammation (Figure 3). In contrast, colonic
inflammation did not alter the expression level of
TRPV1 in the urinary bladder (Figure 3).
Colonic inflammation-induced BDNF expression in the
dorsal root ganglia was attenuated by prolonged pre-
treatment with RTX
Our previous studies (37) showed that the BDNF mRNA
level was increased in the L1 and S1 DRG at 3 days of
colitis. However BDNF protein level was only increased
in the L1 DRG but not in the S1 DRG at this time
point. Conversely, BDNF protein was increased in the
S1 spinal cord due to BDNF release from the S1 DRG
(37). To examine the phenotype of BDNF immunoreac-
tive neurons in the DRG in order to validate a role of
BDNF in sensory plasticity, we performed double immu-
nostaining of BDNF and the nociceptive marker TRPV1
in the L1 DRG at 3 days of colitis. Results showed that
BDNF immunoreactivity was expressed in nociceptors
identified by TRPV1 immunostaining (Figure 4C, yellow
cells, white arrows). Virtually all BDNF was expressed in
TRPV1 neurons; however, a subpopulation of TRPV1
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Page 4 of 14immunoreactive neurons (Figure 4C, green cells, red
arrows) did not express BDNF.
To examine if the activation of TRPV1 primary affer-
ents (presumably C-fibers) had a role in BDNF up-regu-
lation in sensory neurons during colonic inflammation,
we determined the level of BDNF in animals treated
with vehicle (10% Tween-80, 10% ethanol, and normal
saline) + 50% EtOH (Figure 5A), vehicle + TNBS (Figure
5B), RTX + EtOH (Figure 5C), or RTX + TNBS (Figure
5D). Animals were pre-treated with either vehicle or
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Figure 1 Histologic changes and TRPV1 immunoreactivity in the distal colon and the urinary bladder during colonic inflammation.
TNBS treatment resulted in inflammatory response of the distal colon (A-B) and increased immunoreactivity of TRPV1 in the distal colon (E-F).
Colonic inflammation was not accompanied by bladder inflammation (C-D), or changes in the TRPV1 immunoreactivity in the urinary bladder (G-
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μm in E-H. *, p < 0.05.
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Page 5 of 14RTX for one week and then were treated with either
EtOH or TNBS for 3 days. The BDNF expression was
examined by immunohistochemistry. Results showed
that prolonged pre-treatment with RTX significantly
attenuated colonic inflammation-induced BDNF up-reg-
ulation examined in L1 DRG (Figure 5E). RTX had no
effects on the expression level of BDNF in DRG from
non-inflamed animals (Figure 5E).
Blockade of BDNF attenuated colonic inflammation-
induced bladder overactivity
In conscious animals, colonic inflammation significantly
decreased the micturition intervals when compared to
control (control: 220.6 ± 12.1 seconds; TNBS: 81.2 6 ±
2.8 seconds; p < 0.01; Figure 6 and 7A). During colonic
inflammation, animals also exhibited non-voiding con-
tractions (arrows in Figure 6Aa), which were not seen in
control animals (Figure 6Ba). To confirm the results, the
micturition frequency was independently counted and
calculated as 4.9 ± 0.3 times within a 1000-second time
period prior to TNBS treatment. The micturition fre-
quency was increased by 2.5-fold at day 3 post induction
of colonic inflammation (Figure 7B). During micturition,
the quantity of urine voided was weighed by a scale
included in the system, and was automatically recorded
by the program (Figure 6Ab, Bb). TNBS treatment signif-
icantly reduced the amount of each voiding (Figure 7C).
The role of BDNF in mediating bladder function was
examined by intrathecal infusion of BDNF neutralizing
antibody to the spinal cord with an osmotic-pump.
Results showed that BDNF neutralizing antibody par-
tially reversed the decreases in micturition intervals
caused by colonic inflammation (Figure 8A). BDNF anti-
body treatment also reversed the reduction in the quan-
tity of urine per voiding during colonic inflammation
(Figure 8B). Since the up-regulation of BDNF in the
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pre-absorption assay showing that pre-incubation of TRPV1 antibody with a TRPV1 control peptide completely abolished the TRPV1-like
immunoreactivity detected in the inflamed distal colon (compare B to A). Double immunostaining of the transverse section of the inflamed
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Page 7 of 14DRG of the inflamed animals was blocked by pre-treat-
ment with RTX (Figure 5), we examined the effects of
RTX pre-treatment on bladder activity during colonic
inflammation. When the animals were pretreated with
intracolonic instillation of RTX one week prior to
induction of colonic inflammation, the decreases in mic-
turition intervals were reversed to normal level (Figure
8C). The antagonism of RTX also reversed the reduction
in the quantity of urine per voiding during colonic
inflammation (Figure 8D).
Discussion
The present study demonstrates that colonic inflamma-
tion increases the expression level of TRPV1 in the
distal colon but not in the urinary bladder. Colonic
inflammation-induced BDNF is expressed in TRPV1
nociceptive neurons and is attenuated by blockade of
primary afferent activity with prolonged pre-treatment
with RTX. Neutralization of BDNF in the DRG/spinal
cord with intrathecal infusion of a BDNF antibody
reverses bladder overactivity during colonic inflamma-
tion. These results suggest a role of primary afferent
-mediated BDNF up-regulation in viscero-visceral cross-
organ sensitization.
BDNF is a member of the neurotrophin family of
growth factors consisting of nerve growth factor (NGF),
neurotrophin-3 (NT-3) and NT-4. It has long been
implied that BDNF plays a significant role in neuronal
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Page 8 of 14plasticity especially the long-term potentiation (LTP) of
the central nervous system [42]. Recent studies have
also suggested a role of BDNF in modulating sensory
activity in the peripheral nervous system. After periph-
eral inflammation, BDNF is synthesized in the primary
sensory neurons in DRG where it facilitates intracellular
signal transduction and gene expression at the dorsal
horn of the spinal cord via anterograde transport
[37,43,44]. As demonstrated in the present study, BDNF
in the DRG is mainly expressed in TRPV1 nociceptive
neurons. Blockade of primary afferents with the neuro-
toxin RTX reverses the BDNF up-regulation in the DRG
during colonic inflammation, suggesting that signaling
arising from the inflamed distal colon facilitates BDNF
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and others have demonstrated that colonic inflammation
increases the level of NGF and/or neural activity in the
inflamed colon [34,45,46]. NGF receptor TrkA is able to
retrogradely transport from the inflamed colon to the
DRG [34], where it may activate intracellular signaling
molecules and regulate neuronal plasticity. The role of
NGF/TrkA in regulating BDNF expression in the DRG
has also been illustrated by previous studies showing
that NGF treatment increases BDNF expression in the
TrkA/CGRP peptidergic DRG neurons and almost 90%
of TrkA DRG neurons express BDNF [47].
In addition to changes in the neurochemical coding of
the sensory neurons during colonic inflammation, one
of the major physiological alterations accompanying
colonic inflammation is the bladder hyperactivity
[7,11,12]. Analysis of cystometrograms reveals that the
average inter-micturition intervals in control animals are
220 seconds when we infuse the urinary bladder with a
saline solution at a speed of 9 mL/h. This paradigm
results in, by calculation, an average of 0.55 mL infusing
volume per micturition cycle, which is close to the
directly measured amount of solution voided (an average
of 0.537 g per micturition cycle). These results indicate
that there was no leakage of solution into the abdomen
from the intravesicle catheter insertion site during saline
infusion. During colonic inflammation, we have found
that the inter-micturition intervals are decreased and
the quantity of urine voided is also decreased suggesting
bladder overactivity in these animals. The bladder over-
activity in colonic inflamed animals has also been con-
firmed via a non-invasive procedure in which the urine
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Page 10 of 14is collected naturally onto an underneath filter paper
directly from the unrestrained nonoperated animals
(Additional file 1). Analysis of the urine spots on the fil-
ter paper reveals that the animals excrete fewer times (i.
e., lower number of urine drops) with larger volumes
per drop (i.e., bigger urine spots) before induction of
colonic inflammation. TNBS-treated animals void more
frequently (i.e., higher number of urine drops) with
smaller quantities of urine per voiding (i.e., smaller
urine spots) (Additional file 1). Both techniques used in
t h ec u r r e n ts t u d yd e m o n s t r a t et h a tc o l o n i ci n f l a m m a -
tion indeed induces bladder hyperactivity with minimum
change in the morphology of the urinary organ, suggest-
ing a neurogenic mechanism in colon-to-bladder cross-
sensitization. It is noteworthy that there are increased
numbers of non-voiding contractions detected in the
inflamed animals. These non-voiding contractions may
be due to the hyperactivity of the urinary bladder per se,
or due to the abdominal contraction pressure transfer-
ence to the viscera in the inflamed animal. Further
examination of the activity of the abdominal wall will
identify the mechanisms.
The mechanisms and pathways that mediate colon-to-
bladder cross-organ sensitization have been vigorously
studied in the past years. A growing body of evidence
suggests that activation of the primary afferent pathway
and a neural cross talk or interaction in the DRG and
spinal cord has a significant role in mediating cross-
organ sensitization [12,14-16,18,19]. The primary affer-
ents that innervate the urinary bladder or the distal
colon are located in the same spinal segments
[19,48,49]. Thus, irritation of one visceral organ, such as
the distal colon in the present study, may lead to activa-
tion of the primary afferent neurons projecting to this
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Page 11 of 14organ and cross-activation of the nearby afferent neu-
rons projecting to a different viscus such as the urinary
bladder. An experiment involving injection of a viral
vector encoding NGF to the urinary bladder demon-
strates that over-expression of NGF triggers the hyper-
sensitivity of remote organs including the distal colon
[6]. During colonic inflammation, the level of NGF is
significantly increased in the distal colon [34,45]; the
elevated NGF may have a role in triggering bladder
hyperactivity by modulating the plasticity of sensory
neurons. Modified bladder spinal reflex may regulate the
detrusor muscle contractility and/or the activity of the
urethral sphincter leading to increased voiding
frequency.
BDNF elevated in the sensory neurons during colonic
inflammation may modulate the bladder sensory activity.
The level of BDNF high affinity receptor TrkB is
increased in bladder afferent neurons during colonic
inflammation [19]. The accumulation of TrkB in bladder
afferent neurons may enhance the responsiveness of
these neurons to BDNF, thus leading to changes in plas-
ticity of these neurons. In DRG neuron culture, BDNF
increases the expression level of CGRP [19], an excita-
tory neurotransmitter that is also up-regulated in the
bladder afferent neurons during colonic inflammation
[19], suggesting a possible role of BDNF in modulating
bladder afferent excitability.
The role of BDNF in regulating visceral sensitivity has
been suggested by a previous study showing that intra-
peritoneal injection of BDNF neutralizing antibody
attenuates colonic inflammation-induced colonic hyper-
sensitivity [40]. To specifically target the BDNF that is
expressed in the DRG and spinal cord [37], in the pre-
sent study a specific BDNF neutralizing antibody was
infused into the DRG/spinal space under the dural
membrane. This treatment regime also blocks colonic
inflammation-induced bladder hyperactivity. BDNF that
is up-regulated in the sensory neurons following colonic
irritation may be released into the extracellular space
within the DRG and the spinal cord. The action of
BDNF is then blocked by the intrathecal BDNF antibody
that further blocks the sensitivity of the bladder afferent
neurons and modulates the urinary bladder function.
Bladder afferent nerves consist of myelinated Aδ-fibers
and unmyelinated C-fibers projecting to the lumbosacral
spinal level which is also of major importance in con-
trolling colonic function [50,51]. Activation of the C-
fibers during colonic inflammation is apparent from our
studies showing that the level of TRPV1 is significantly
increased in nerve fibers in the inflamed distal colon.
Blockade of the activity of these nerves with prolonged
pre-treatment with RTX has also blocked colonic
inflammation-induced bladder overactivity.
Conclusion
The present study demonstrates that colonic inflamma-
tion causes neurogenic bladder overactivity. This cross-
organ sensitization is regulated by primary afferent-
mediated BDNF up-regulation in the DRG/spinal cord.
T h ef i n d i n g si nt h ec u r r e n ts t u d ys u g g e s tap o t e n t i a l
t h e r a p e u t i cr o l eo fB D N Fa n a l o g si nt h et r e a t m e n to f
visceral hypersensitivity.
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